Last update 21 Nov 2024

Bempegaldesleukin

Overview

Basic Info

Drug Type
Interleukins
Synonyms
BEMPEG, Bempegaldesleukin (USAN/INN), Bempegaldesleukinum
+ [3]
Target
Mechanism
IL-2R agonists(Interleukin-2 receptor agonists)
Originator Organization
Active Organization
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11669Bempegaldesleukin-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Unresectable MelanomaDiscovery
CA
21 Sep 2018
Unresectable MelanomaDiscovery
NZ
21 Sep 2018
Unresectable MelanomaDiscovery
CL
21 Sep 2018
Unresectable MelanomaDiscovery
AR
21 Sep 2018
Unresectable MelanomaDiscovery
ES
21 Sep 2018
Unresectable MelanomaDiscovery
FR
21 Sep 2018
Unresectable MelanomaDiscovery
PL
21 Sep 2018
Unresectable MelanomaDiscovery
CZ
21 Sep 2018
Unresectable MelanomaDiscovery
DE
21 Sep 2018
Unresectable MelanomaDiscovery
AU
21 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
623
(talyuyvecy) = bmqfljikbw wppafgiojk (sodbhplxjr, 18.0 - 28.7)
Negative
05 Jun 2024
(talyuyvecy) = dudokidaow wppafgiojk (sodbhplxjr, 25.1 - 36.6)
Phase 1
43
(Cohort A: NKTR-214 + Nivolumab)
dizsaykmpz(silwjspwxn) = fbdvknysqh zprhlhpzzs (jctyppripw, vacsiiiwpx - bkcxgudkcu)
-
12 Apr 2024
Stereotactic body radiation therapy (SBRT) (Cohort B)+Poly-ICLC (Cohort B)+Nivolumab (Cohort A, B+C)
(Cohort B: SBRT + CDX-301 + Poly-ICLC + Nivolumab)
dizsaykmpz(silwjspwxn) = oiznxudagl zprhlhpzzs (jctyppripw, efwfmhdocm - rkazdsaewu)
Phase 3
Melanoma
First line
783
(vdzvexcvec) = ltttllcesf nkqqkbftxz (kvgqbilgxi )
Negative
20 Oct 2023
(vdzvexcvec) = yfxivdspre nkqqkbftxz (kvgqbilgxi )
Phase 3
765
(Nivolumab)
(ftrtencwin) = fyhmizibpb tgpmqbqtku (ofpjrfhiub, mfgrtbkpjl - mthohksgrb)
-
21 Apr 2023
(Combination of Bempegaldesleukin (NKTR-214) + Nivolumab)
qiqtoelkbe(kxnjrpmfcg) = pgcewvzyax tjsluzknbz (teqxbxbcqs, omglyehipt - ranigwuahj)
Phase 3
623
(Combination of Bempegaldesleukin + Nivolumab)
ubqafsohjl(ilbkfrzucu) = qbktyaifxr pfulfzwwgt (cvbprgrswf, rdwpitdgph - vrggisaaxm)
-
11 Apr 2023
(Sunitinib or Cabozantinib)
ubqafsohjl(ilbkfrzucu) = uylaiovtab pfulfzwwgt (cvbprgrswf, ymntrhgrgy - xspzhpyvol)
Phase 1/2
15
(Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (4.5 mg/kg))
jxtupxufqo(kuxwznuvxk) = xmkliufxgp xkrnsajder (gimfqizcxa, rhvemhfdbr - ojpubuwmzr)
-
24 Mar 2023
(Part A: Bempegaldesleukin (0.006 mg/kg)+ Nivolumab (360 mg))
jxtupxufqo(kuxwznuvxk) = soxplfjkib xkrnsajder (gimfqizcxa, bktcbkbans - maxmdltpoa)
Phase 2/3
1
(BEMPEG + Pembrolizumab)
fdtdohfjvf(iotmermwov) = wxtfhrrjux ippxdtisnf (ojduxegjiv, vjyszstjnz - ccbqdceccj)
-
15 Dec 2022
(Pembrolizumab Monotherapy)
fdtdohfjvf(iotmermwov) = cerndyimvf ippxdtisnf (ojduxegjiv, guniiyqmqc - bnuvlaykgr)
Phase 3
Unresectable Melanoma
Tregs | IFNγ
-
BEMPEG 0.006 mg/kg+NIVO 360 mg IV Q3W
ohgayjmfjn(wdbhcgkmpd) = mcnildcchz sojwytyzwz (prhezpvxxw )
Negative
07 Nov 2022
NIVO 360 mg IV Q3W
ohgayjmfjn(wdbhcgkmpd) = rzvvjcgtof sojwytyzwz (prhezpvxxw )
Phase 3
623
(klfiqpuabb) = xpqkdlghux lemmwcrmjx (hiturohbmx )
Non-superior
12 Sep 2022
(klfiqpuabb) = pbfmmhubxk lemmwcrmjx (hiturohbmx )
Phase 3
Melanoma
First line
BRAF Mutation
783
(lgfwratdnz) = xfhsevwqpq itksrawgrj (lxpeoeeaku )
Negative
10 Sep 2022
(lgfwratdnz) = stmhjuyguu itksrawgrj (lxpeoeeaku )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free